Is end-of-life anticipatory prescribing always enough?
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Abstract
End-of-life anticipatory prescribing can give patients timely access to symptom relieving drugs in their last days and hours, but improved review, provision, and personalisation of medication is needed, write Ben Bowers and colleagues
Description
Keywords
Journal Title
BMJ
Conference Name
Journal ISSN
0959-8138
1756-1833
1756-1833
Volume Title
Publisher
BMJ
Publisher DOI
Rights and licensing
Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
BB is supported by the Wellcome Trust [225577/Z/22/Z]. SB is supported by the National Institute for Health and Care Research Applied Research Collaboration East of England (NIHR ARC EoE) at Cambridgeshire and Peterborough NHS Foundation Trust.